Keywords
.Acute myeloid leukemia
Molecular Targeted Therapy
Safety
Efficacy
How to Cite
Abstract
Introduction. Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with poor survival rates, especially in relapsed/refractory cases. While CAR-T cell therapy has transformed the management of other hematologic cancers, its application in AML remains limited, due to antigen heterogeneity and safety concerns. Methods. This systematic review analyzed 43 studies published between 2020 and 2024 to evaluate the efficacy and safety of CAR-T cell therapies targeting antigens such as CLL-1, CD33, CD123, and CD70 in AML. Data were extracted on survival outcomes, adverse events and antigen-specific responses. Results. CLL-1 demonstrated the most favorable outcomes, with a 60% survival response at 6.2 months in adults and 75% in pediatric patients. CD33 and CD123 showed moderate efficacy but were associated with higher hematologic toxicities. CD70 exhibited promising response rates but significant side effects (85% in preclinical studies). Emerging antigens like B7-H3 and dual-target strategies showed potential to improve outcomes by addressing antigen escape and tumor heterogeneity. Conclusions. CAR-T therapies targeting CLL-1 are highly promising for AML, offering high specificity and manageable toxicity. However, broader clinical adoption requires addressing challenges related to antigen variability and safety. In Colombia, the implementation of CAR-T therapies could revolutionize AML management but requires overcoming barriers such as cost, infrastructure, and local research capacity.
References
Vakiti A, Reynolds SB, Mewawalla P. Acute myeloid leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev [Internet]. 2019;36:70–87. Available from: http://dx.doi.org/10.1016/j.blre.2019.04.005
Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. J Hematol Oncol [Internet]. 2022;15(1):88. Available from: http://dx.doi.org/10.1186/s13045-022-01308-1
Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med [Internet]. 2009;361(13):1249–59. Available from: http://dx.doi.org/10.1056/NEJMoa0904544
Zuo S, Li C, Sun X, Deng B, Zhang Y, Han Y, et al. C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial. Nat Commun [Internet]. 2024;15(1):6155. Available from: http://dx.doi.org/10.1038/s41467-024-50485-9
Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol [Internet]. 2019;94(7):803–11. Available from: http://dx.doi.org/10.1002/ajh.25484
Appelbaum J, Price AE, Oda K, Zhang J, Leung W-H, Tampella G, et al. Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing. J Clin Invest [Internet]. 2024;134(9). Available from: http://dx.doi.org/10.1172/JCI162593
Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol [Internet]. 2023;14:1188049. Available from: http://dx.doi.org/10.3389/fimmu.2023.1188049
Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev [Internet]. 2022;18(2):e1230. Available from: http://dx.doi.org/10.1002/cl2.1230
Moher D, Liberati A, Tetzlaff J. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med. 2009;6(7).
Zhang H, Wang P, Li Z, He Y, Gan W, Jiang H. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed/refractory acute myeloid leukemia. Clin Cancer Res [Internet]. 2021;27(13):3549–55. Available from: http://dx.doi.org/10.1158/1078-0432.CCR-20-4543
Liu Y, Wang S, Schubert M-L, Lauk A, Yao H, Blank MF, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer [Internet]. 2022;150(7):1141–55. Available from: http://dx.doi.org/10.1002/ijc.33865
Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, et al. Cytokine-mediated CAR T therapy resistance in AML. Nat Med [Internet]. 2024;30(12):3697–708. Available from: http://dx.doi.org/10.1038/s41591-024-03271-5
Sugita M, Galetto R, Zong H, Ewing-Crystal N, Trujillo-Alonso V, Mencia-Trinchant N, et al. Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nat Commun [Internet]. 2022;13(1):2227. Available from: http://dx.doi.org/10.1038/s41467-022-29668-9
Wu G, Guo S, Luo Q, Wang X, Deng W, Ouyang G, et al. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Front Immunol [Internet]. 2023;14:1093750. Available from: http://dx.doi.org/10.3389/fimmu.2023.1093750
Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood [Internet]. 2021;138(4):318–30. Available from: http://dx.doi.org/10.1182/blood.2020008221
Warda W, Da Rocha MN, Trad R, Haderbache R, Salma Y, Bouquet L, et al. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. Cancer Gene Ther [Internet]. 2021;28(12):1365–75. Available from: http://dx.doi.org/10.1038/s41417-020-00284-3
Lichtman EI, Du H, Shou P, Song F, Suzuki K, Ahn S, et al. Preclinical evaluation of B7-H3-specific chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Clin Cancer Res [Internet]. 2021;27(11):3141–53. Available from: http://dx.doi.org/10.1158/1078-0432.CCR-20-2540
Wen J, Chen Y, Yang J, Dai C, Yu S, Zhong W, et al. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia. J Immunother Cancer [Internet]. 2023;11(7):e006857. Available from: http://dx.doi.org/10.1136/jitc-2023-006857
Danylesko I, Shem-Tov N, Yerushalmi R, Jacoby E, Toren A, Shouval R, et al. Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression. Curr Res Transl Med [Internet]. 2024;72(4):103471. Available from: http://dx.doi.org/10.1016/j.retram.2024.103471
Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, et al. Therapeutic targeting of mesothelin with chimeric antigen receptor T cells in acute myeloid leukemia. Clin Cancer Res [Internet]. 2021;27(20):5718–30. Available from: http://dx.doi.org/10.1158/1078-0432.CCR-21-1546
An N, Pan Y, Yang L, Zhang Q, Deng S, Zhang Q, et al. Anti-acute myeloid leukemia activity of CD38-CAR-T cells with PI3Kδ downregulation. Mol Pharm [Internet]. 2023;20(5):2426–35. Available from: http://dx.doi.org/10.1021/acs.molpharmaceut.2c00913
Lu Y, Liu Y, Wen S, Kuang N, Zhang X, Li J, et al. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML). J Transl Med [Internet]. 2022;20(1):600. Available from: http://dx.doi.org/10.1186/s12967-022-03797-7
Ataca Atilla P, McKenna MK, Tashiro H, Srinivasan M, Mo F, Watanabe N, et al. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer [Internet]. 2020;8(2):e001229. Available from: http://dx.doi.org/10.1136/jitc-2020-001229
Pei K, Xu H, Wang P, Gan W, Hu Z, Su X, et al. Anti-CLL1-based CAR T-cells with 4-1-BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia. Cancer Med [Internet]. 2023;12(8):9655–61. Available from: http://dx.doi.org/10.1002/cam4.5916
Karbowski C, Goldstein R, Frank B, Kim K, Li C-M, Homann O, et al. Nonclinical safety assessment of AMG 553, an investigational chimeric antigen receptor T-cell therapy for the treatment of acute myeloid leukemia. Toxicol Sci [Internet]. 2020;177(1):94–107. Available from: http://dx.doi.org/10.1093/toxsci/kfaa098
Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, et al. Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target. Nat Cancer [Internet]. 2023;4(11):1592–609. Available from: http://dx.doi.org/10.1038/s43018-023-00652-6
Meyer J-E, Loff S, Dietrich J, Spehr J, Jurado Jiménez G, von Bonin M, et al. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML. Oncoimmunology [Internet]. 2021;10(1):1945804. Available from: http://dx.doi.org/10.1080/2162402X.2021.1945804
Lee W-HS, Ye Z, Cheung AMS, Goh YPS, Oh HLJ, Rajarethinam R, et al. Effective killing of acute myeloid leukemia by TIM-3 targeted chimeric antigen receptor T cells. Mol Cancer Ther [Internet]. 2021;20(9):1702–12. Available from: http://dx.doi.org/10.1158/1535-7163.MCT-20-0155
Qin H, Yang L, Chukinas JA, Shah N, Tarun S, Pouzolles M, et al. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J Immunother Cancer [Internet]. 2021;9(9):e003149. Available from: http://dx.doi.org/10.1136/jitc-2021-003149
Nixdorf D, Sponheimer M, Berghammer D, Engert F, Bader U, Philipp N, et al. Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML. Leukemia [Internet]. 2023;37(6):1298–310. Available from: http://dx.doi.org/10.1038/s41375-023-01905-0
Kirkey DC, Loeb AM, Castro S, McKay CN, Perkins L, Pardo L, et al. Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia. Blood Adv [Internet]. 2023;7(7):1178–89. Available from: http://dx.doi.org/10.1182/bloodadvances.2022008304
Ghamari A, Pakzad P, Majd A, Ebrahimi M, Hamidieh AA. Design and production an effective bispecific tandem chimeric antigen receptor on T cells against CD123 and folate receptor ß towards B-acute myeloid leukaemia blasts. Cell J [Internet]. 2021;23(6):650–7. Available from: http://dx.doi.org/10.22074/cellj.2021.7314
Towers R, Trombello L, Fusenig M, Tunger A, Baumann A-L, Savoldelli R, et al. Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8+ clonal effector and CAR T-cell function while promoting a senescence-associated phenotype. Cancer Immunol Immunother [Internet]. 2024;73(1):8. Available from: http://dx.doi.org/10.1007/s00262-023-03594-1
Wang X-Y, Bian M-R, Lin G-Q, Yu L, Zhang Y-M, Wu D-P. Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia. Eur J Haematol [Internet]. 2024;112(1):83–93. Available from: http://dx.doi.org/10.1111/ejh.14104
Tang L, Kong Y, Wang H, Zou P, Sun T, Liu Y, et al. Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia. Front Immunol [Internet]. 2023;14:1145441. Available from: http://dx.doi.org/10.3389/fimmu.2023.1145441
Yan Z, Gu R, Ma H, Chen N, Zhang T, Xu Y, et al. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells. Cell Oncol [Internet]. 2024;47(5):1879–95. Available from: http://dx.doi.org/10.1007/s13402-024-00971-5
Magnani CF, Myburgh R, Brunn S, Chambovey M, Ponzo M, Volta L, et al. Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. Mol Ther Oncolytics [Internet]. 2023;30:56–71. Available from: http://dx.doi.org/10.1016/j.omto.2023.07.003
Pe KCS, Jewmoung S, Rad SAH, Chantarat N, Chanswangphuwana C, Tashiro H, et al. Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy. Biomed Pharmacother [Internet]. 2024;179(117388):117388. Available from: http://dx.doi.org/10.1016/j.biopha.2024.117388
Lin G, Zhang Y, Yu L, Wu D. Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia. Mol Med Rep [Internet]. 2021;23(3):1. Available from: http://dx.doi.org/10.3892/mmr.2021.11847
Dao T, Xiong G, Mun SS, Meyerberg J, Korontsvit T, Xiang J, et al. A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML. Blood [Internet]. 2024;143(6):507–21. Available from: http://dx.doi.org/10.1182/blood.2023021054
Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, et al. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. Cell Rep Med [Internet]. 2024;5(6):101572. Available from: http://dx.doi.org/10.1016/j.xcrm.2024.101572
Sun X, Wang G, Zuo S, Niu Q, Chen X, Feng X. Preclinical evaluation of CD64 as a potential target for CAR-T-cell therapy for acute myeloid leukemia. J Immunother [Internet]. 2022;45(2):67–77. Available from: http://dx.doi.org/10.1097/CJI.0000000000000406
Vaidya A, Doherty E, Wu X, Huang S, Hebbar N, Thanekar U, et al. Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation. Haematologica [Internet]. 2023;108(4):1039–52. Available from: http://dx.doi.org/10.3324/haematol.2021.279301
Xie D, Jin X, Sun R, Zhang M, Lu W, Cao X, et al. Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape. Transl Oncol [Internet]. 2023;34:101695. Available from: http://dx.doi.org/10.1016/j.tranon.2023.101695
Chen N, Xu Y, Mou J, Rao Q, Xing H, Tian Z, et al. Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood Cancer J [Internet]. 2021;11(8):144. Available from: http://dx.doi.org/10.1038/s41408-021-00536-x
Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer [Internet]. 2022;10(7). Available from: http://dx.doi.org/10.1136/jitc-2021-004222
Fan S, Wang T, You F, Zhang T, Li Y, Ji C, et al. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia. Eur J Med Res [Internet]. 2023;28(1):129. Available from: http://dx.doi.org/10.1186/s40001-023-01049-y
Teppert K, Yonezawa Ogusuku IE, Brandes C, Herbel V, Winter N, Werchau N, et al. CAR’TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment. Mol Ther Oncol [Internet]. 2024;32(2):200797. Available from: http://dx.doi.org/10.1016/j.omton.2024.200797
Townsend MH, Shrestha G, Robison RA, O’Neill KL. The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res [Internet]. 2018;37(1):163. Available from: http://dx.doi.org/10.1186/s13046-018-0817-0
Atilla E, Benabdellah K. The black hole: CAR T cell therapy in AML. Cancers (Basel) [Internet]. 2023;15(10). Available from: http://dx.doi.org/10.3390/cancers15102713
Park YP, Jin L, Bennett KB, Wang D, Fredenburg KM, Tseng JE, et al. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma. Oral Oncol [Internet]. 2018;78:145–50. Available from: http://dx.doi.org/10.1016/j.oraloncology.2018.01.024
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar